WILMINGTON, Del. — In a federal class action, shareholders say directors are selling Celgene Corp. too cheaply through an unfair process to Bristol-Myers Squibb, for $50 a share plus a 1-for-1 share swap, a $74 billion merger. Bristol-Myers Squibb is not a party to the complaint.
- Huge Power Outage in Venezuela Raises Tensions
- Minimum Wage